1. Quinpramine is a novel compound effective in ameliorating brain autoimmune disease
- Author
-
Anne K. Mausberg, Olaf Stüve, Mahendra Pal Singh, Peter Gmeiner, Carsten Korth, Bernd C. Kieseier, Todd N. Eagar, Ralf Klingenstein, Petra D. Cravens, Wei Hu, Gerd Meyer zu Hörste, and Stefan Löber
- Subjects
Drug ,Encephalomyelitis, Autoimmune, Experimental ,T-Lymphocytes ,media_common.quotation_subject ,Disease ,Central nervous system disease ,Mice ,Developmental Neuroscience ,Immunopathology ,medicine ,Animals ,Quinpramine ,Cell Proliferation ,Glycoproteins ,media_common ,Autoimmune disease ,Autoimmune encephalitis ,business.industry ,Quinolinium Compounds ,Multiple sclerosis ,medicine.disease ,Peptide Fragments ,Mice, Inbred C57BL ,Disease Models, Animal ,Neurology ,Immunology ,Cytokines ,Female ,Myelin-Oligodendrocyte Glycoprotein ,business - Abstract
Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNgamma and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.
- Published
- 2009